Advertisement
Use of Yescarta in Acute Lymphoblastic Leukemia
Yescarta (axicabtagene ciloleucel) is also under late Phase 1 research for treatment of refractory or relapsed acute lymphoblastic leukemia (r/r ALL).
ALL is a blood and bone marrow cancer that results in a multiplication of immature lymphocytes that are ineffective in fighting infections. Lymphoblasts crowd the bone marrow and prevent normal blood cells from forming. Healthy red blood cells from the bone marrow cannot be formed, leading to anemia.
There are several approaches to treatment of ALL:
- Blood transfusions
- Chemotherapy, targeted cancer therapy
- Radiation treatment
- Stem cell transplant
In patients who are refractory to these standard treatments or relapse after receiving them, CAR T-cell therapy may offer a last-chance hope for successful treatment.
